ADMA Biologics, Inc.
ADMA
$22.33
$0.602.76%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 117.55M | 119.84M | 107.19M | 81.88M | 73.90M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 117.55M | 119.84M | 107.19M | 81.88M | 73.90M |
| Cost of Revenue | 54.22M | 60.18M | 49.74M | 42.77M | 40.72M |
| Gross Profit | 63.33M | 59.66M | 57.45M | 39.11M | 33.19M |
| SG&A Expenses | 24.59M | 19.58M | 17.55M | 16.64M | 15.52M |
| Depreciation & Amortization | 25.00K | 28.00K | 142.00K | 193.00K | 187.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.23M | 80.20M | 67.99M | 60.05M | 56.87M |
| Operating Income | 38.32M | 39.64M | 39.20M | 21.82M | 17.03M |
| Income Before Tax | 34.71M | 36.75M | 35.85M | 18.40M | -17.65M |
| Income Tax Expenses | -77.18M | 840.00K | 3.79M | 595.00K | -- |
| Earnings from Continuing Operations | 111.90M | 35.91M | 32.06M | 17.81M | -17.65M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 111.90M | 35.91M | 32.06M | 17.81M | -17.65M |
| EBIT | 38.32M | 39.64M | 39.20M | 21.82M | 17.03M |
| EBITDA | 40.27M | 41.58M | 41.25M | 23.94M | 19.14M |
| EPS Basic | 0.47 | 0.15 | 0.14 | 0.08 | -0.08 |
| Normalized Basic EPS | 0.10 | 0.10 | 0.10 | 0.05 | 0.03 |
| EPS Diluted | 0.46 | 0.15 | 0.13 | 0.08 | -0.08 |
| Normalized Diluted EPS | 0.09 | 0.09 | 0.09 | 0.05 | 0.03 |
| Average Basic Shares Outstanding | 236.43M | 234.57M | 232.42M | 228.87M | 225.97M |
| Average Diluted Shares Outstanding | 245.90M | 244.80M | 242.17M | 236.41M | 225.97M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |